Article

Which Patients with Atopic Dermatitis Are Least Likely to Outgrow It?

Author(s):

Childhood atopic dermatitis (AD) usually resolves before adulthood, a meta-analysis of cases showed. Those patients who did see their AD persist were more likely to be female, to have been older at onset, and to have relatively severe AD.

Some patients are more likely than others to have their childhood skin ailments last for decades.

A new meta-analysis identifies the initial duration of atopic dermatitis (AD), as well as age of onset and gender among factors associated with the disease persisting into adulthood.

The systematic review and meta-analysis from the Dermatology Foundation examining 45 studies of over 100,000 subjects was published by lead investigator Jonathan Silverberg,MD, PhD, MPH

Northwestern University Feinberg School of Medicine, Chicago, IL and colleagues in the October issue of the Journal of the American Academy of Dermatology.

While it is generally held that most children with atopic dermatitis will grow out of having the disease, the researchers indicate, "much of the data to support this notion originate from smaller studies, and did not account for a number of clinical factors that might modify disease persistence."

Noting recent studies which have suggested that AD may persist more commonly than previously recognized, Silverberg and colleagues undertook the review and meta-analysis to determine rates of disease persistence over time and to identify the clinical factors that may help to predict persistence.

The 45 studies identified for review were from 15 countries and included 110,651 subjects spanning 434,992 patient-years. The subject age at initial diagnosis ranged from 0.04 to 17.5 years (mean 1.6 ± 1.3 years), with AD diagnosed in 87.7 percent of subjects by age of 5 years. Duration of follow-up ranged from 0.25 to 23 years (mean 3.9 ± 2.8 years), with follow-up of 5 years or longer in 55.7 percent of studies and 10 years or longer in 20.8 percent of studies.

Patients with longer initial durations of AD were found more likely to subsequently have longer courses of the disease. In comparison to those having 3 years of persistent AD whose condition then persisted an additional mean 3.2 years, those with durations of 5 or 10 years experienced an additional mean 6.8 ± 0.06 years, or 8.3 ± 0.08 years respectively.

The risk for persistence was also found to be greater when disease onset was either at age 2 to 5 years or 12 to 17 years, compared to age of onset of 0 to 1 year. Females were more likely to have AD persist, with mean 12.7 ± 0.2 years compared to males with mean 11.7 ± 0.2 years.

Only three studies had data on persistence relative to severity, and these indicated that there was greater risk for persistence with more severe disease at diagnosis. Six studies considered, and found no relation between persistence of AD and sensitivity to allergens, as reflected in skin-prick testing and/or antigen-specific IgE.

Silverberg and colleagues note that while they found disease severity, older age of onset, and female gender as risk factors for persistent AD, they also determined that 80 percent of childhood AD did not persist beyond 8 years, and less than 5 percent persisted 20 years after diagnosis.

Reference

Persistence of atopic dermatitis (AD): A systematic review and meta-analysis

Further Coverage:

Childhood Atopic Dermatitis does not Commonly Continue to Adulthood

Asthma Predisposition High Among Children with Food Allergies

Predicting and Preventing Atopic Dermatitis in Children

Related Videos
Monica Kraft, MD: Discussing Phase 3b Findings on Albuterol/Budesonide for Asthma
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD
© 2024 MJH Life Sciences

All rights reserved.